OVID — Ovid Therapeutics Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2017-05-05.
Performance
Technicals
Others in Healthcare
Measured signals that fired on OVID
| date | signal | measured base rate |
|---|---|---|
| 2026-08-13 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-04-13 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-18 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-05 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-06 | Carter Charles Ross Chief Financial Officer | Grant or award | 50.0K | 0.00 | 0 |
| 2026-04-07 | Fitzgerald Kevin Joseph Director | Grant or award | 17.6K | 2.56 | 45.0K |
| 2026-04-07 | PAPADOPOULOS STELIOS Director | Grant or award | 17.6K | 2.56 | 45.0K |
| 2026-04-07 | Friedman Bart Director | Grant or award | 8.8K | 2.56 | 22.5K |
| 2026-03-23 | LEVIN JEREMY M Executive Chairman | Option exercise | 47.3K | 1.40 | 66.3K |
| 2026-02-26 | Rona Jeffrey A CBFO | Grant or award | 68.1K | 0.00 | 0 |
| 2026-02-23 | ALEXANDER MARGARET A. President and CEO | Open-market sale | 11.7K | 1.45 | 16.9K |
| 2026-02-23 | Rona Jeffrey A CBFO | Open-market sale | 8.5K | 1.45 | 12.4K |
| 2025-12-15 | LEVIN JEREMY M CEO | Conversion | 71.0K | — | — |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | Conversion | 1.2M | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23.8M | 10.7M |
| JANUS HENDERSON GROUP PLC | 23.7M | 10.7M |
| Affinity Asset Advisors, LLC | 23.6M | 10.6M |
| EVENTIDE ASSET MANAGEMENT, LLC | 22.0M | 9.9M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 13.7M | 6.2M |
| Balyasny Asset Management L.P. | 12.3M | 5.5M |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.7M | 5.3M |
| ADAR1 Capital Management, LLC | 10.1M | 4.5M |
| Saturn V Capital Management LP | 9.2M | 4.2M |
| FEDERATED HERMES, INC. | 7.9M | 3.6M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 144 | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-13 | 2026-08-11 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Ovid Therapeutics Inc. (OVID) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about OVID
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →